00:00For the first time in over two decades, the FDA has approved a genuinely new way to treat ADHD.
00:06The drug is called Simtrio, and it just became the first-ever triple reuptake inhibitor cleared
00:11for the condition, acting on three brain chemicals at once—dopamine, norepinephrine,
00:17and serotonin. That third target is what makes this different. Every stimulant on the market
00:22today focuses mainly on dopamine and norepinephrine. Simtrio's developer, Otsuka Pharmaceutical,
00:28says adding serotonin regulation helped patients in clinical trials with more than just focus.
00:35It improved emotional control and executive function, too. The approval covers adults and
00:40children as young as six who weigh at least 44 pounds, opening a new option for roughly 22.5
00:47million Americans living with ADHD, many of whom stop taking their current medication because of
00:53side effects or because it simply stops working. The drug does carry boxed warnings.
00:58Doctors must monitor pediatric patients for suicidal thoughts. And because it's a CNS stimulant,
01:05it still needs a final scheduling decision from the DEA before it hits pharmacy shelves.
01:11Otsuka expects Simtrio to be commercially available later this year. For the ADHD community,
01:17doctors are calling this the biggest treatment shakeup since the early 2000s.
01:21Disclosure. This video contains stock footage and content created or enhanced using AI-assisted tools.
Comments